Dermatopathology Pearls: Report From the AAD Meeting

Article Type
Changed
Thu, 01/10/2019 - 13:44
Display Headline
Dermatopathology Pearls: Report From the AAD Meeting

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
Publications

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
Publications
Publications
Article Type
Display Headline
Dermatopathology Pearls: Report From the AAD Meeting
Display Headline
Dermatopathology Pearls: Report From the AAD Meeting
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

Neuromodulation Patient Outcomes: Report From the AAD Meeting

Article Type
Changed
Thu, 01/10/2019 - 13:44
Display Headline
Neuromodulation Patient Outcomes: Report From the AAD Meeting

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
Publications

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
Publications
Publications
Article Type
Display Headline
Neuromodulation Patient Outcomes: Report From the AAD Meeting
Display Headline
Neuromodulation Patient Outcomes: Report From the AAD Meeting
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

Eye disease affects 1 in 5 adults with severe atopic dermatitis

Article Type
Changed
Fri, 01/18/2019 - 16:57

 

Results of a large cohort study in Denmark found that adults with atopic dermatitis (AD) were significantly more likely to be affected by certain ocular conditions, compared with those who did not have AD.

“Keratitis, conjunctivitis, and keratoconus as well as cataracts in patients younger than 50 years occurred more frequently in patients with AD and in a disease severity–dependent manner,” concluded the authors, who wrote that as far as they know, this is the largest study conducted to date of ocular disorders in adults with AD.

Dr. Jacob Thyssen
The findings, published in June, are based on a population-based sample of 4.25 million adults in Denmark, using national health care and prescription registries, of whom 5,766 had been diagnosed with mild AD and another 4,272 with severe AD. The researchers, led by Jacob Thyssen, MD, PhD, of the department of dermatology and allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark, found that 12% of patients with mild AD and 19% of those with severe AD were prescribed at least one anti-inflammatory ocular medication commonly used to treat conjunctivitis or keratitis, compared with only 4.5% of those without AD (J Am Acad Dermatol. 201 Aug;77[2]:280-6).

The investigators also found an elevated risk of a keratitis diagnosis among patients with mild AD (hazard ratio, 1.66; 95% confidence interval, 1.15-2.40) and those with severe AD (HR, 3.17; 95% CI, 2.31-4.35). Severe AD was associated with an elevated risk of keratoconus (HR, 10.01; 95% CI, 5.02-19.96),

Cataracts and glaucoma were not more common among those with AD overall. However, cataracts were increased among those under age 50 years with mild and severe AD, which were significant associations for both, but not among those over age 50 with AD. There were no differences for glaucoma risk associated with AD by age.

The investigators acknowledged that the study could not capture the reasons why anti-inflammatory ocular medicines were prescribed and that such medicines could have been prescribed for conditions other than the ocular conditions.

Capturing the risk of ocular diseases in AD is important, they wrote. They referred to “emerging concern” about the incidence of conjunctivitis with “near-future” biologic treatments for AD and the potential for long-term consequences. They referred to adverse event data from randomized clinical trials of dupilumab, an interleukin-4 receptor–alpha antagonist, approved by the Food and Drug Administration in March 2017 for treatment of moderate to severe AD, which included more cases of conjunctivitis among those treated with the biologic, compared with those on placebo (N Engl J Med. 2016 Dec 15;375:2335-48). A “weak trend” for more cases of conjunctivitis was also reported among treated patients with an IL-13 inhibitor, lebrikizumab, in a phase 2 study of adults with AD, they wrote.

Treatments targeting IL-4 receptor–alpha have been shown to result in increased blood eosinophil counts, and “these elevations might have clinical effects,” Dr. Thyssen and his colleagues wrote, adding: “Notably, eosinophils are pathognomonic for allergic eye disease.”

Dr. Thyssen disclosed funding from the Lundbeck Foundation and honoraria from Roche, Sanofi Genzyme, and LEO Pharma. Three other authors on the study reported research funding and/or honoraria from pharmaceutical firms.

Publications
Topics
Sections

 

Results of a large cohort study in Denmark found that adults with atopic dermatitis (AD) were significantly more likely to be affected by certain ocular conditions, compared with those who did not have AD.

“Keratitis, conjunctivitis, and keratoconus as well as cataracts in patients younger than 50 years occurred more frequently in patients with AD and in a disease severity–dependent manner,” concluded the authors, who wrote that as far as they know, this is the largest study conducted to date of ocular disorders in adults with AD.

Dr. Jacob Thyssen
The findings, published in June, are based on a population-based sample of 4.25 million adults in Denmark, using national health care and prescription registries, of whom 5,766 had been diagnosed with mild AD and another 4,272 with severe AD. The researchers, led by Jacob Thyssen, MD, PhD, of the department of dermatology and allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark, found that 12% of patients with mild AD and 19% of those with severe AD were prescribed at least one anti-inflammatory ocular medication commonly used to treat conjunctivitis or keratitis, compared with only 4.5% of those without AD (J Am Acad Dermatol. 201 Aug;77[2]:280-6).

The investigators also found an elevated risk of a keratitis diagnosis among patients with mild AD (hazard ratio, 1.66; 95% confidence interval, 1.15-2.40) and those with severe AD (HR, 3.17; 95% CI, 2.31-4.35). Severe AD was associated with an elevated risk of keratoconus (HR, 10.01; 95% CI, 5.02-19.96),

Cataracts and glaucoma were not more common among those with AD overall. However, cataracts were increased among those under age 50 years with mild and severe AD, which were significant associations for both, but not among those over age 50 with AD. There were no differences for glaucoma risk associated with AD by age.

The investigators acknowledged that the study could not capture the reasons why anti-inflammatory ocular medicines were prescribed and that such medicines could have been prescribed for conditions other than the ocular conditions.

Capturing the risk of ocular diseases in AD is important, they wrote. They referred to “emerging concern” about the incidence of conjunctivitis with “near-future” biologic treatments for AD and the potential for long-term consequences. They referred to adverse event data from randomized clinical trials of dupilumab, an interleukin-4 receptor–alpha antagonist, approved by the Food and Drug Administration in March 2017 for treatment of moderate to severe AD, which included more cases of conjunctivitis among those treated with the biologic, compared with those on placebo (N Engl J Med. 2016 Dec 15;375:2335-48). A “weak trend” for more cases of conjunctivitis was also reported among treated patients with an IL-13 inhibitor, lebrikizumab, in a phase 2 study of adults with AD, they wrote.

Treatments targeting IL-4 receptor–alpha have been shown to result in increased blood eosinophil counts, and “these elevations might have clinical effects,” Dr. Thyssen and his colleagues wrote, adding: “Notably, eosinophils are pathognomonic for allergic eye disease.”

Dr. Thyssen disclosed funding from the Lundbeck Foundation and honoraria from Roche, Sanofi Genzyme, and LEO Pharma. Three other authors on the study reported research funding and/or honoraria from pharmaceutical firms.

 

Results of a large cohort study in Denmark found that adults with atopic dermatitis (AD) were significantly more likely to be affected by certain ocular conditions, compared with those who did not have AD.

“Keratitis, conjunctivitis, and keratoconus as well as cataracts in patients younger than 50 years occurred more frequently in patients with AD and in a disease severity–dependent manner,” concluded the authors, who wrote that as far as they know, this is the largest study conducted to date of ocular disorders in adults with AD.

Dr. Jacob Thyssen
The findings, published in June, are based on a population-based sample of 4.25 million adults in Denmark, using national health care and prescription registries, of whom 5,766 had been diagnosed with mild AD and another 4,272 with severe AD. The researchers, led by Jacob Thyssen, MD, PhD, of the department of dermatology and allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark, found that 12% of patients with mild AD and 19% of those with severe AD were prescribed at least one anti-inflammatory ocular medication commonly used to treat conjunctivitis or keratitis, compared with only 4.5% of those without AD (J Am Acad Dermatol. 201 Aug;77[2]:280-6).

The investigators also found an elevated risk of a keratitis diagnosis among patients with mild AD (hazard ratio, 1.66; 95% confidence interval, 1.15-2.40) and those with severe AD (HR, 3.17; 95% CI, 2.31-4.35). Severe AD was associated with an elevated risk of keratoconus (HR, 10.01; 95% CI, 5.02-19.96),

Cataracts and glaucoma were not more common among those with AD overall. However, cataracts were increased among those under age 50 years with mild and severe AD, which were significant associations for both, but not among those over age 50 with AD. There were no differences for glaucoma risk associated with AD by age.

The investigators acknowledged that the study could not capture the reasons why anti-inflammatory ocular medicines were prescribed and that such medicines could have been prescribed for conditions other than the ocular conditions.

Capturing the risk of ocular diseases in AD is important, they wrote. They referred to “emerging concern” about the incidence of conjunctivitis with “near-future” biologic treatments for AD and the potential for long-term consequences. They referred to adverse event data from randomized clinical trials of dupilumab, an interleukin-4 receptor–alpha antagonist, approved by the Food and Drug Administration in March 2017 for treatment of moderate to severe AD, which included more cases of conjunctivitis among those treated with the biologic, compared with those on placebo (N Engl J Med. 2016 Dec 15;375:2335-48). A “weak trend” for more cases of conjunctivitis was also reported among treated patients with an IL-13 inhibitor, lebrikizumab, in a phase 2 study of adults with AD, they wrote.

Treatments targeting IL-4 receptor–alpha have been shown to result in increased blood eosinophil counts, and “these elevations might have clinical effects,” Dr. Thyssen and his colleagues wrote, adding: “Notably, eosinophils are pathognomonic for allergic eye disease.”

Dr. Thyssen disclosed funding from the Lundbeck Foundation and honoraria from Roche, Sanofi Genzyme, and LEO Pharma. Three other authors on the study reported research funding and/or honoraria from pharmaceutical firms.

Publications
Publications
Topics
Article Type
Sections
Article Source

FROM THE JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Vitals

 

Key clinical point: Conjunctivitis, keratitis, and keratoconus are common in patients with atopic dermatitis, compared with the general population

Major finding: 19% of adults with severe AD received a prescription for an anti-inflammatory eye medication, compared with 4.5% of the general population.

Data source: Epidemiologic data from more than 4 million patients in Danish health care and prescription registries.

Disclosures: Four investigators disclosed outside grant funding and/or financial relationships with pharmaceutical manufacturers.

Disqus Comments
Default

Why three strategies to correct vaccination hesitancy failed

Article Type
Changed
Fri, 01/18/2019 - 16:57

 

Three strategies to correct vaccination hesitancy failed in a small study, supporting findings in the literature that misinformation tends to linger in the memory and efforts to dislodge it may in fact reinforce it.

Publications
Topics
Sections

 

Three strategies to correct vaccination hesitancy failed in a small study, supporting findings in the literature that misinformation tends to linger in the memory and efforts to dislodge it may in fact reinforce it.

 

Three strategies to correct vaccination hesitancy failed in a small study, supporting findings in the literature that misinformation tends to linger in the memory and efforts to dislodge it may in fact reinforce it.

Publications
Publications
Topics
Article Type
Sections
Article Source

FROM PLOS ONE

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

Oral antibiotics successfully treat community-acquired pneumonia with empyema

Article Type
Changed
Fri, 01/18/2019 - 16:57

 

– Outpatient oral antibiotics were more successful than outpatient parenteral antibiotic therapy at treating children with community-acquired pneumonia complicated by empyema, in a study presented at the annual meeting of the European Society for Paediatric Infectious Diseases.

Thirty-five percent of the patients were culture positive, a typically low rate that makes treatment of this disease particularly challenging, Lauren Kushner, a medical student at the University of California, Irvine, and one of the study’s authors, said at the meeting.

The treatment success rates, which were defined as improvement with no change in treatment, were 93% for the patients taking oral antibiotics and 58% in the patients on outpatient parenteral antibiotic therapy.

This retrospective observational study included 149 patients under age 18 years hospitalized for community-acquired pneumonia complicated by empyema, at Children’s Hospital of Orange County, Calif. Only 12 of the patients were treated with parenteral antibiotic therapy and none of the study participants had comorbid chronic medical conditions. As in other studies, Streptococcus pneumoniae was the most commonly identified pathogen.

Laboratory markers of inflammation are useful in guiding oral antibiotic therapy for children with CAP complicated by empyema, reported Ms. Kushner.

“A rapid drop in C-reactive protein [CRP] in combination with a decrease in white blood cell count [WBC] can be used acutely in the hospitalization phase to tell you the patient is improving on the selected antibiotic and also to help dictate when the patient might be able to go home, whereas improvement in the erythrocyte sedimentation rate [ESR] does not happen until much later in the course of treatment but can be used to tell you when a patient has been adequately treated,” said Ms. Kushner.

One hundred thirty-seven patients were discharged on oral antibiotic therapy, as is strongly recommended in Infectious Diseases Society of America guidelines for postdischarge treatment of complicated pneumonia, even though there are no randomized clinical trials demonstrating it to be superior or even noninferior to outpatient parenteral antibiotics. An aminopenicillin was the most frequently prescribed type of oral antibiotic, while ceftriaxone was the top choice for outpatient parenteral therapy.

The average total duration of antibiotic therapy, inpatient plus outpatient, was similar in the two groups: 30.4 days in the oral antibiotic group and 33.2 days in children on outpatient IV therapy.

The transition to oral therapy occurred a median of 6 days after admission. At that point, CRP levels had dropped sharply by a mean of 204 mg/L from a baseline of more than 250 mg/L at admission. In the same time frame, mean WBC dropped by 6,400 cells/mcL from close to 20,000/mcL at admission. Thus, sharp declines in these two inflammatory markers while a patient is still in the hospital provide reassurance that antibiotic therapy is on the right track. Their rate of decline slowed considerably after the switch to oral therapy: for example, mean CRP decreased by only another 44 mg/L from switch to discharge, and by a further 19 mg/L from discharge to end of treatment.

In contrast, the mean ESR remained elevated at a level approaching 100 mm/hour with little fluctuation from admission through discharge. Weekly monitoring of ESR post discharge showed that this inflammatory marker improved only late in the course of oral therapy. A drop to less than 30 mm/hour indicates the infection has resolved, Ms. Kushner said.

She noted that in contrast to her study findings, a recent multicenter, 2,123-patient study by the Pediatric Research in Inpatient Settings Network found that treatment failure rates didn’t differ significantly between the two treatment strategies (Pediatrics. 2016 Dec;138[6]. pii: e20161692). Similarly, a retrospective study of 391 children with empyema admitted to Primary Children’s Hospital in Salt Lake City found closely similar rates of treatment failure and other complications regardless of whether the patients were placed on outpatient oral or parenteral antibiotic therapy (Hosp Pediatr. 2015 Dec;5[12]:605-12).

Ms. Kushner reported having no financial conflicts of interest regarding the study.

Meeting/Event
Publications
Topics
Sections
Meeting/Event
Meeting/Event

 

– Outpatient oral antibiotics were more successful than outpatient parenteral antibiotic therapy at treating children with community-acquired pneumonia complicated by empyema, in a study presented at the annual meeting of the European Society for Paediatric Infectious Diseases.

Thirty-five percent of the patients were culture positive, a typically low rate that makes treatment of this disease particularly challenging, Lauren Kushner, a medical student at the University of California, Irvine, and one of the study’s authors, said at the meeting.

The treatment success rates, which were defined as improvement with no change in treatment, were 93% for the patients taking oral antibiotics and 58% in the patients on outpatient parenteral antibiotic therapy.

This retrospective observational study included 149 patients under age 18 years hospitalized for community-acquired pneumonia complicated by empyema, at Children’s Hospital of Orange County, Calif. Only 12 of the patients were treated with parenteral antibiotic therapy and none of the study participants had comorbid chronic medical conditions. As in other studies, Streptococcus pneumoniae was the most commonly identified pathogen.

Laboratory markers of inflammation are useful in guiding oral antibiotic therapy for children with CAP complicated by empyema, reported Ms. Kushner.

“A rapid drop in C-reactive protein [CRP] in combination with a decrease in white blood cell count [WBC] can be used acutely in the hospitalization phase to tell you the patient is improving on the selected antibiotic and also to help dictate when the patient might be able to go home, whereas improvement in the erythrocyte sedimentation rate [ESR] does not happen until much later in the course of treatment but can be used to tell you when a patient has been adequately treated,” said Ms. Kushner.

One hundred thirty-seven patients were discharged on oral antibiotic therapy, as is strongly recommended in Infectious Diseases Society of America guidelines for postdischarge treatment of complicated pneumonia, even though there are no randomized clinical trials demonstrating it to be superior or even noninferior to outpatient parenteral antibiotics. An aminopenicillin was the most frequently prescribed type of oral antibiotic, while ceftriaxone was the top choice for outpatient parenteral therapy.

The average total duration of antibiotic therapy, inpatient plus outpatient, was similar in the two groups: 30.4 days in the oral antibiotic group and 33.2 days in children on outpatient IV therapy.

The transition to oral therapy occurred a median of 6 days after admission. At that point, CRP levels had dropped sharply by a mean of 204 mg/L from a baseline of more than 250 mg/L at admission. In the same time frame, mean WBC dropped by 6,400 cells/mcL from close to 20,000/mcL at admission. Thus, sharp declines in these two inflammatory markers while a patient is still in the hospital provide reassurance that antibiotic therapy is on the right track. Their rate of decline slowed considerably after the switch to oral therapy: for example, mean CRP decreased by only another 44 mg/L from switch to discharge, and by a further 19 mg/L from discharge to end of treatment.

In contrast, the mean ESR remained elevated at a level approaching 100 mm/hour with little fluctuation from admission through discharge. Weekly monitoring of ESR post discharge showed that this inflammatory marker improved only late in the course of oral therapy. A drop to less than 30 mm/hour indicates the infection has resolved, Ms. Kushner said.

She noted that in contrast to her study findings, a recent multicenter, 2,123-patient study by the Pediatric Research in Inpatient Settings Network found that treatment failure rates didn’t differ significantly between the two treatment strategies (Pediatrics. 2016 Dec;138[6]. pii: e20161692). Similarly, a retrospective study of 391 children with empyema admitted to Primary Children’s Hospital in Salt Lake City found closely similar rates of treatment failure and other complications regardless of whether the patients were placed on outpatient oral or parenteral antibiotic therapy (Hosp Pediatr. 2015 Dec;5[12]:605-12).

Ms. Kushner reported having no financial conflicts of interest regarding the study.

 

– Outpatient oral antibiotics were more successful than outpatient parenteral antibiotic therapy at treating children with community-acquired pneumonia complicated by empyema, in a study presented at the annual meeting of the European Society for Paediatric Infectious Diseases.

Thirty-five percent of the patients were culture positive, a typically low rate that makes treatment of this disease particularly challenging, Lauren Kushner, a medical student at the University of California, Irvine, and one of the study’s authors, said at the meeting.

The treatment success rates, which were defined as improvement with no change in treatment, were 93% for the patients taking oral antibiotics and 58% in the patients on outpatient parenteral antibiotic therapy.

This retrospective observational study included 149 patients under age 18 years hospitalized for community-acquired pneumonia complicated by empyema, at Children’s Hospital of Orange County, Calif. Only 12 of the patients were treated with parenteral antibiotic therapy and none of the study participants had comorbid chronic medical conditions. As in other studies, Streptococcus pneumoniae was the most commonly identified pathogen.

Laboratory markers of inflammation are useful in guiding oral antibiotic therapy for children with CAP complicated by empyema, reported Ms. Kushner.

“A rapid drop in C-reactive protein [CRP] in combination with a decrease in white blood cell count [WBC] can be used acutely in the hospitalization phase to tell you the patient is improving on the selected antibiotic and also to help dictate when the patient might be able to go home, whereas improvement in the erythrocyte sedimentation rate [ESR] does not happen until much later in the course of treatment but can be used to tell you when a patient has been adequately treated,” said Ms. Kushner.

One hundred thirty-seven patients were discharged on oral antibiotic therapy, as is strongly recommended in Infectious Diseases Society of America guidelines for postdischarge treatment of complicated pneumonia, even though there are no randomized clinical trials demonstrating it to be superior or even noninferior to outpatient parenteral antibiotics. An aminopenicillin was the most frequently prescribed type of oral antibiotic, while ceftriaxone was the top choice for outpatient parenteral therapy.

The average total duration of antibiotic therapy, inpatient plus outpatient, was similar in the two groups: 30.4 days in the oral antibiotic group and 33.2 days in children on outpatient IV therapy.

The transition to oral therapy occurred a median of 6 days after admission. At that point, CRP levels had dropped sharply by a mean of 204 mg/L from a baseline of more than 250 mg/L at admission. In the same time frame, mean WBC dropped by 6,400 cells/mcL from close to 20,000/mcL at admission. Thus, sharp declines in these two inflammatory markers while a patient is still in the hospital provide reassurance that antibiotic therapy is on the right track. Their rate of decline slowed considerably after the switch to oral therapy: for example, mean CRP decreased by only another 44 mg/L from switch to discharge, and by a further 19 mg/L from discharge to end of treatment.

In contrast, the mean ESR remained elevated at a level approaching 100 mm/hour with little fluctuation from admission through discharge. Weekly monitoring of ESR post discharge showed that this inflammatory marker improved only late in the course of oral therapy. A drop to less than 30 mm/hour indicates the infection has resolved, Ms. Kushner said.

She noted that in contrast to her study findings, a recent multicenter, 2,123-patient study by the Pediatric Research in Inpatient Settings Network found that treatment failure rates didn’t differ significantly between the two treatment strategies (Pediatrics. 2016 Dec;138[6]. pii: e20161692). Similarly, a retrospective study of 391 children with empyema admitted to Primary Children’s Hospital in Salt Lake City found closely similar rates of treatment failure and other complications regardless of whether the patients were placed on outpatient oral or parenteral antibiotic therapy (Hosp Pediatr. 2015 Dec;5[12]:605-12).

Ms. Kushner reported having no financial conflicts of interest regarding the study.

Publications
Publications
Topics
Article Type
Click for Credit Status
Ready
Sections
Article Source

AT ESPID 2017

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Vitals

 

Key clinical point: Large reductions in inflammatory markers are helpful signposts in managing pediatric community-acquired pneumonia complicated by empyema.

Major finding: The treatment success rate with outpatient oral antibiotic therapy for pediatric community-acquired pneumonia with empyema was 93% in a retrospective study, significantly better than the 58% rate in a much smaller group of patients discharged with outpatient parenteral antibiotic therapy.

Data source: This retrospective single-center study included 149 patients under age 18 years hospitalized for community-acquired pneumonia complicated by empyema and later sent home on either oral or parenteral antibiotic therapy.

Disclosures: The study presenter reported having no financial conflicts of interest.

Disqus Comments
Default

VHA warns California clinicians on assisted suicide

Article Type
Changed
Fri, 01/04/2019 - 13:39

 

– The Veterans Health Administration has issued strict rules forbidding clinicians from doing anything to help patients kill themselves via physician-assisted suicide, which is now legal in certain cases in California, according to a psychiatrist who updated colleagues at the annual meeting of the American Psychiatric Association.

The VHA says clinicians may not make referrals to physicians who help patients commit suicide, said Kristin Beizai, MD, who is affiliated with the VA San Diego Healthcare System. Nor can they provide information about patient diagnoses outside of medical records or complete forms to support physician aid-in-dying (PAD), she said.

The VA San Diego system received queries from patients about assisted suicide even before the law in mid-2016 allowed physicians to provide deadly medications to some patients, said Dr. Beizai, who’s also with the University of California, San Diego.

“There was a lot of attention coming before the law was active,” she said, and more questions from patients arose after that time.

In addition to California, four other states (Colorado, Oregon, Vermont, and Washington) – and the District of Columbia – allow terminally ill people who meet certain conditions to commit suicide with the assistance of physicians. In addition, a court ruling in Montana appears to allow PAD there.

California’s law allowing PAD took effect after Gov. Jerry Brown in 2015 signed a bill passed by the legislature.

According to a recent report from the state of California, 111 people killed themselves during June-December 2016 by taking deadly medication prescribed by physicians. The patients must self-administer the medications. Of those 111 people, 90% were white, and most had college degrees. The majority had cancer.

The report also said 173 physicians had written 191 total lethal prescriptions, suggesting some patients – perhaps dozens – had not taken the drugs by the end of 2016.

In response to a query from Dr. Beizai about policies regarding PAD, VHA ethics officials sent word that clinicians must butt out when it comes to assisted suicide: “No practitioner functioning within his or her scope of duty may participate in fulfilling requests for euthanasia or PAD,” they said, regardless of what state law allows.

According to the VHA:

  • Clinicians may not support PAD through any means, including referrals and evaluations, and federal funds may not be used for PAD.
  • Clinicians cannot fill out forms supporting PAD. However, they must not hinder the release of medical records when requested by an outside provider.
  • Patients can seek PAD outside of the VHA system if they wish. Patients who ask about PAD must be told that the VHA doesn’t offer the service. “We need to inform them very directly that we do not provide it and are not allowed to participate,” Dr. Beizai said.
  • If a patient makes a request regarding PAD, the VHA clinician “must explore the source of the patient’s request and respond with the best possible, medically appropriate care that is consistent with legal standards and is legally permissible.”

Clinicians are encouraged to explore issues like pain, depression, fears, and anxiety, Dr. Beizai said. The VHA has set up a six-step protocol on this front.

But the VHA is making it clear that patients who seek PAD elsewhere must not be abandoned. “Don’t disconnect from the patients if they determine they want to go that route,” said Dr. Beizai, who gave that message to VA San Diego staffers during an educational outreach program regarding PAD.

Dr. Beizai reported no relevant disclosures.

Meeting/Event
Publications
Topics
Sections
Meeting/Event
Meeting/Event

 

– The Veterans Health Administration has issued strict rules forbidding clinicians from doing anything to help patients kill themselves via physician-assisted suicide, which is now legal in certain cases in California, according to a psychiatrist who updated colleagues at the annual meeting of the American Psychiatric Association.

The VHA says clinicians may not make referrals to physicians who help patients commit suicide, said Kristin Beizai, MD, who is affiliated with the VA San Diego Healthcare System. Nor can they provide information about patient diagnoses outside of medical records or complete forms to support physician aid-in-dying (PAD), she said.

The VA San Diego system received queries from patients about assisted suicide even before the law in mid-2016 allowed physicians to provide deadly medications to some patients, said Dr. Beizai, who’s also with the University of California, San Diego.

“There was a lot of attention coming before the law was active,” she said, and more questions from patients arose after that time.

In addition to California, four other states (Colorado, Oregon, Vermont, and Washington) – and the District of Columbia – allow terminally ill people who meet certain conditions to commit suicide with the assistance of physicians. In addition, a court ruling in Montana appears to allow PAD there.

California’s law allowing PAD took effect after Gov. Jerry Brown in 2015 signed a bill passed by the legislature.

According to a recent report from the state of California, 111 people killed themselves during June-December 2016 by taking deadly medication prescribed by physicians. The patients must self-administer the medications. Of those 111 people, 90% were white, and most had college degrees. The majority had cancer.

The report also said 173 physicians had written 191 total lethal prescriptions, suggesting some patients – perhaps dozens – had not taken the drugs by the end of 2016.

In response to a query from Dr. Beizai about policies regarding PAD, VHA ethics officials sent word that clinicians must butt out when it comes to assisted suicide: “No practitioner functioning within his or her scope of duty may participate in fulfilling requests for euthanasia or PAD,” they said, regardless of what state law allows.

According to the VHA:

  • Clinicians may not support PAD through any means, including referrals and evaluations, and federal funds may not be used for PAD.
  • Clinicians cannot fill out forms supporting PAD. However, they must not hinder the release of medical records when requested by an outside provider.
  • Patients can seek PAD outside of the VHA system if they wish. Patients who ask about PAD must be told that the VHA doesn’t offer the service. “We need to inform them very directly that we do not provide it and are not allowed to participate,” Dr. Beizai said.
  • If a patient makes a request regarding PAD, the VHA clinician “must explore the source of the patient’s request and respond with the best possible, medically appropriate care that is consistent with legal standards and is legally permissible.”

Clinicians are encouraged to explore issues like pain, depression, fears, and anxiety, Dr. Beizai said. The VHA has set up a six-step protocol on this front.

But the VHA is making it clear that patients who seek PAD elsewhere must not be abandoned. “Don’t disconnect from the patients if they determine they want to go that route,” said Dr. Beizai, who gave that message to VA San Diego staffers during an educational outreach program regarding PAD.

Dr. Beizai reported no relevant disclosures.

 

– The Veterans Health Administration has issued strict rules forbidding clinicians from doing anything to help patients kill themselves via physician-assisted suicide, which is now legal in certain cases in California, according to a psychiatrist who updated colleagues at the annual meeting of the American Psychiatric Association.

The VHA says clinicians may not make referrals to physicians who help patients commit suicide, said Kristin Beizai, MD, who is affiliated with the VA San Diego Healthcare System. Nor can they provide information about patient diagnoses outside of medical records or complete forms to support physician aid-in-dying (PAD), she said.

The VA San Diego system received queries from patients about assisted suicide even before the law in mid-2016 allowed physicians to provide deadly medications to some patients, said Dr. Beizai, who’s also with the University of California, San Diego.

“There was a lot of attention coming before the law was active,” she said, and more questions from patients arose after that time.

In addition to California, four other states (Colorado, Oregon, Vermont, and Washington) – and the District of Columbia – allow terminally ill people who meet certain conditions to commit suicide with the assistance of physicians. In addition, a court ruling in Montana appears to allow PAD there.

California’s law allowing PAD took effect after Gov. Jerry Brown in 2015 signed a bill passed by the legislature.

According to a recent report from the state of California, 111 people killed themselves during June-December 2016 by taking deadly medication prescribed by physicians. The patients must self-administer the medications. Of those 111 people, 90% were white, and most had college degrees. The majority had cancer.

The report also said 173 physicians had written 191 total lethal prescriptions, suggesting some patients – perhaps dozens – had not taken the drugs by the end of 2016.

In response to a query from Dr. Beizai about policies regarding PAD, VHA ethics officials sent word that clinicians must butt out when it comes to assisted suicide: “No practitioner functioning within his or her scope of duty may participate in fulfilling requests for euthanasia or PAD,” they said, regardless of what state law allows.

According to the VHA:

  • Clinicians may not support PAD through any means, including referrals and evaluations, and federal funds may not be used for PAD.
  • Clinicians cannot fill out forms supporting PAD. However, they must not hinder the release of medical records when requested by an outside provider.
  • Patients can seek PAD outside of the VHA system if they wish. Patients who ask about PAD must be told that the VHA doesn’t offer the service. “We need to inform them very directly that we do not provide it and are not allowed to participate,” Dr. Beizai said.
  • If a patient makes a request regarding PAD, the VHA clinician “must explore the source of the patient’s request and respond with the best possible, medically appropriate care that is consistent with legal standards and is legally permissible.”

Clinicians are encouraged to explore issues like pain, depression, fears, and anxiety, Dr. Beizai said. The VHA has set up a six-step protocol on this front.

But the VHA is making it clear that patients who seek PAD elsewhere must not be abandoned. “Don’t disconnect from the patients if they determine they want to go that route,” said Dr. Beizai, who gave that message to VA San Diego staffers during an educational outreach program regarding PAD.

Dr. Beizai reported no relevant disclosures.

Publications
Publications
Topics
Article Type
Sections
Article Source

AT APA

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

When families participate in rounds, errors decrease

Article Type
Changed
Thu, 12/06/2018 - 18:44

 

– When families are actively included in pediatric hospital rounds, preventable adverse events drop 38% and families report better hospital experiences, with no negative impact on rounds duration or teaching, according to a prospective investigation on inpatient pediatric units of seven North American hospitals.

Dr. Alisa Khan
“We [found] that families are excellent reporters of safety, which is an important takeaway for hospitals and hospitalists,” said lead researcher Alisa Khan, MD, from the division of general pediatrics at Boston Children’s Hospital.

“We always talk about how parents know their children better than anyone else; empowering the family to know what we are looking for can have downstream safety implications,” she said. In the study, families often caught problems before medical staff, such as IV infiltrations. They also reported delays in diagnoses and conflicting information, among other things, Dr. Khan explained at the Pediatric Hospital Medicine meeting.

There’s not much data on family-centered rounds in pediatric medicine, so Dr. Khan and her team decided to investigate. They modified the I-PASS resident handoff model (illness severity; patient summary; action list; situation awareness and contingency planning; and synthesis by receiver) to be more family friendly.

Families were given a short form before rounds that asked if their child was better, worse, or about the same as the day before, and what questions and items they wanted to address. There was also space for them to take notes during the presentation about what had changed overnight, what still needed to be done, and what to look out for.

Families were given the opportunity to speak first during rounds, and medical staff used plain language: “has a fever” instead of “febrile,” for instance. At the end of the presentation, families were asked to read back their take-aways.

The investigators compared baseline data from the 3 months before implementation with data for the 3 months afterward. The study included more than 1,500 patients and more than 300 rounds in both the pre- and postimplementation arms. The children were general inpatients; surgery and ICU patients were excluded.

Harmful errors/preventable AEs dropped from 20.7/1,000 patients days to 12.9/1,000 after implementation, a 38% reduction (P = .01). There was also a reduction in overall AEs from 34 to 18.5/1,000 patient-days (P = .002).

Compared with baseline data, after implementation, families were more likely to report that they understood the medical plan and what was said on rounds. They also were more likely to report that nurses had addressed their concerns and made them feel like an important member of the team.

Direct observation of pre- and postimplementation rounds showed that family and nursing engagement improved and families more often got written updates. There were no statistically significant differences in rounds duration or decreases in teaching.

“Congratulations. This is very impressive work, and also the right thing to do,” an audience member said after Dr. Khan’s presentation at the meeting, sponsored by the Society of Hospital Medicine, the American Academy of Pediatrics, and the Academic Pediatric Association.

The work was funded by the Patient-Centered Outcomes Research Institute and the Agency for Healthcare Research and Quality. Dr. Khan had no disclosures.

Meeting/Event
Publications
Topics
Sections
Meeting/Event
Meeting/Event

 

– When families are actively included in pediatric hospital rounds, preventable adverse events drop 38% and families report better hospital experiences, with no negative impact on rounds duration or teaching, according to a prospective investigation on inpatient pediatric units of seven North American hospitals.

Dr. Alisa Khan
“We [found] that families are excellent reporters of safety, which is an important takeaway for hospitals and hospitalists,” said lead researcher Alisa Khan, MD, from the division of general pediatrics at Boston Children’s Hospital.

“We always talk about how parents know their children better than anyone else; empowering the family to know what we are looking for can have downstream safety implications,” she said. In the study, families often caught problems before medical staff, such as IV infiltrations. They also reported delays in diagnoses and conflicting information, among other things, Dr. Khan explained at the Pediatric Hospital Medicine meeting.

There’s not much data on family-centered rounds in pediatric medicine, so Dr. Khan and her team decided to investigate. They modified the I-PASS resident handoff model (illness severity; patient summary; action list; situation awareness and contingency planning; and synthesis by receiver) to be more family friendly.

Families were given a short form before rounds that asked if their child was better, worse, or about the same as the day before, and what questions and items they wanted to address. There was also space for them to take notes during the presentation about what had changed overnight, what still needed to be done, and what to look out for.

Families were given the opportunity to speak first during rounds, and medical staff used plain language: “has a fever” instead of “febrile,” for instance. At the end of the presentation, families were asked to read back their take-aways.

The investigators compared baseline data from the 3 months before implementation with data for the 3 months afterward. The study included more than 1,500 patients and more than 300 rounds in both the pre- and postimplementation arms. The children were general inpatients; surgery and ICU patients were excluded.

Harmful errors/preventable AEs dropped from 20.7/1,000 patients days to 12.9/1,000 after implementation, a 38% reduction (P = .01). There was also a reduction in overall AEs from 34 to 18.5/1,000 patient-days (P = .002).

Compared with baseline data, after implementation, families were more likely to report that they understood the medical plan and what was said on rounds. They also were more likely to report that nurses had addressed their concerns and made them feel like an important member of the team.

Direct observation of pre- and postimplementation rounds showed that family and nursing engagement improved and families more often got written updates. There were no statistically significant differences in rounds duration or decreases in teaching.

“Congratulations. This is very impressive work, and also the right thing to do,” an audience member said after Dr. Khan’s presentation at the meeting, sponsored by the Society of Hospital Medicine, the American Academy of Pediatrics, and the Academic Pediatric Association.

The work was funded by the Patient-Centered Outcomes Research Institute and the Agency for Healthcare Research and Quality. Dr. Khan had no disclosures.

 

– When families are actively included in pediatric hospital rounds, preventable adverse events drop 38% and families report better hospital experiences, with no negative impact on rounds duration or teaching, according to a prospective investigation on inpatient pediatric units of seven North American hospitals.

Dr. Alisa Khan
“We [found] that families are excellent reporters of safety, which is an important takeaway for hospitals and hospitalists,” said lead researcher Alisa Khan, MD, from the division of general pediatrics at Boston Children’s Hospital.

“We always talk about how parents know their children better than anyone else; empowering the family to know what we are looking for can have downstream safety implications,” she said. In the study, families often caught problems before medical staff, such as IV infiltrations. They also reported delays in diagnoses and conflicting information, among other things, Dr. Khan explained at the Pediatric Hospital Medicine meeting.

There’s not much data on family-centered rounds in pediatric medicine, so Dr. Khan and her team decided to investigate. They modified the I-PASS resident handoff model (illness severity; patient summary; action list; situation awareness and contingency planning; and synthesis by receiver) to be more family friendly.

Families were given a short form before rounds that asked if their child was better, worse, or about the same as the day before, and what questions and items they wanted to address. There was also space for them to take notes during the presentation about what had changed overnight, what still needed to be done, and what to look out for.

Families were given the opportunity to speak first during rounds, and medical staff used plain language: “has a fever” instead of “febrile,” for instance. At the end of the presentation, families were asked to read back their take-aways.

The investigators compared baseline data from the 3 months before implementation with data for the 3 months afterward. The study included more than 1,500 patients and more than 300 rounds in both the pre- and postimplementation arms. The children were general inpatients; surgery and ICU patients were excluded.

Harmful errors/preventable AEs dropped from 20.7/1,000 patients days to 12.9/1,000 after implementation, a 38% reduction (P = .01). There was also a reduction in overall AEs from 34 to 18.5/1,000 patient-days (P = .002).

Compared with baseline data, after implementation, families were more likely to report that they understood the medical plan and what was said on rounds. They also were more likely to report that nurses had addressed their concerns and made them feel like an important member of the team.

Direct observation of pre- and postimplementation rounds showed that family and nursing engagement improved and families more often got written updates. There were no statistically significant differences in rounds duration or decreases in teaching.

“Congratulations. This is very impressive work, and also the right thing to do,” an audience member said after Dr. Khan’s presentation at the meeting, sponsored by the Society of Hospital Medicine, the American Academy of Pediatrics, and the Academic Pediatric Association.

The work was funded by the Patient-Centered Outcomes Research Institute and the Agency for Healthcare Research and Quality. Dr. Khan had no disclosures.

Publications
Publications
Topics
Article Type
Click for Credit Status
Ready
Sections
Article Source

AT PHM 2017

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Vitals

 

Key clinical point: It’s worth the effort to engage families in medical rounds.

Major finding: Harmful errors/preventable AEs dropped from 20.7/1,000 patients days to 12.9 after implementation of a program to engage families in pediatric rounds, a 38% reduction (P = .01).

Data source: More than 600 pediatric inpatient rounds at seven North American hospitals.

Disclosures: The work was funded by the Patient-Centered Outcomes Research Institute and the Agency for Healthcare Research and Quality. The lead investigator had no disclosures.

Disqus Comments
Default

Fat shaming interferes with patients’ medical care, experts say

Article Type
Changed
Fri, 08/11/2017 - 13:59

 

– Stereotypical views held by physicians, psychologists, nurses, and other medical professionals about overweight and obese patients need to change, panelists said at the annual convention of the American Psychological Association.

“We have a lot of negative attitudes toward heavy-weight people. Judging patients as too big or too fat produces physical and mental health effects,” said Joan C. Chrisler, PhD, the Class of ’43 Professor of Psychology at Connecticut College, New London. “Shame and disrespectful treatment can lead to delay in seeking health care, reluctance to return visits, or lower trust in the providers and their recommendations.”

A study of more than 300 autopsy reports showed that obese patients were 1.65 times more likely than normal weight and underweight groups combined were to have medical conditions such as endocarditis, ischemic bowel disease, and lung cancer that were not diagnosed, Dr. Chrisler said in a press release (Am J Clin Pathol. 2006 Jan;125[1]:127-31).

In addition to preventing patients from seeking care, Dr. Chrisler said in the release, unfamiliarity with the dosing adjustments sometimes required on medications based on the body mass index of patients affects the quality of care. She cited a retrospective study showing that emergency physicians frequently underdose common antibiotics in the emergency department (Am J Emerg Med. 2012 Sep;30[7]:1212-4).

Dr. Maureen C. McHugh
Maureen C. McHugh, PhD, stressed the importance of understanding the origins of fat shaming and its destructive effects.

“People aren’t born repulsed by fat people,” said Dr. McHugh, professor of psychology at Indiana University of Pennsylvania. “Fat hate is learned within the family.”

They encouraged more sensitivity from medical professionals when it comes to treating overweight and obese patients, such as providing changing gowns of different sizes in examination rooms and weighing patients in private areas of the medical office.

Dr. Chrisler and Dr. McHugh said weight stigma should be addressed in medicine and psychology through training and research, and in working with patients who are obese. “Treatments should focus on mental and physical health as the desired outcomes for therapy rather than weight,” Dr. McHugh said.

Dr. Chrisler, coauthor of a recent article on sizeism (Fat Studies. 2017 Aug;6[1]:38-53), had no disclosures. Dr. McHugh also had no disclosures.

 

Obesity is a major modifiable cause of diseases of the digestive tract that routinely goes unaddressed. The AGA Obesity Practice Guide was created to support gastroenterologists leading a care team to help patients with obesity achieve a healthy weight. The AGA Obesity Practice Guide provides a comprehensive, multi-disciplinary process to personalize innovative obesity care for safe and effective weight management. Learn more at www.gastro.org/obesity.

Meeting/Event
Publications
Topics
Sections
Meeting/Event
Meeting/Event

 

– Stereotypical views held by physicians, psychologists, nurses, and other medical professionals about overweight and obese patients need to change, panelists said at the annual convention of the American Psychological Association.

“We have a lot of negative attitudes toward heavy-weight people. Judging patients as too big or too fat produces physical and mental health effects,” said Joan C. Chrisler, PhD, the Class of ’43 Professor of Psychology at Connecticut College, New London. “Shame and disrespectful treatment can lead to delay in seeking health care, reluctance to return visits, or lower trust in the providers and their recommendations.”

A study of more than 300 autopsy reports showed that obese patients were 1.65 times more likely than normal weight and underweight groups combined were to have medical conditions such as endocarditis, ischemic bowel disease, and lung cancer that were not diagnosed, Dr. Chrisler said in a press release (Am J Clin Pathol. 2006 Jan;125[1]:127-31).

In addition to preventing patients from seeking care, Dr. Chrisler said in the release, unfamiliarity with the dosing adjustments sometimes required on medications based on the body mass index of patients affects the quality of care. She cited a retrospective study showing that emergency physicians frequently underdose common antibiotics in the emergency department (Am J Emerg Med. 2012 Sep;30[7]:1212-4).

Dr. Maureen C. McHugh
Maureen C. McHugh, PhD, stressed the importance of understanding the origins of fat shaming and its destructive effects.

“People aren’t born repulsed by fat people,” said Dr. McHugh, professor of psychology at Indiana University of Pennsylvania. “Fat hate is learned within the family.”

They encouraged more sensitivity from medical professionals when it comes to treating overweight and obese patients, such as providing changing gowns of different sizes in examination rooms and weighing patients in private areas of the medical office.

Dr. Chrisler and Dr. McHugh said weight stigma should be addressed in medicine and psychology through training and research, and in working with patients who are obese. “Treatments should focus on mental and physical health as the desired outcomes for therapy rather than weight,” Dr. McHugh said.

Dr. Chrisler, coauthor of a recent article on sizeism (Fat Studies. 2017 Aug;6[1]:38-53), had no disclosures. Dr. McHugh also had no disclosures.

 

Obesity is a major modifiable cause of diseases of the digestive tract that routinely goes unaddressed. The AGA Obesity Practice Guide was created to support gastroenterologists leading a care team to help patients with obesity achieve a healthy weight. The AGA Obesity Practice Guide provides a comprehensive, multi-disciplinary process to personalize innovative obesity care for safe and effective weight management. Learn more at www.gastro.org/obesity.

 

– Stereotypical views held by physicians, psychologists, nurses, and other medical professionals about overweight and obese patients need to change, panelists said at the annual convention of the American Psychological Association.

“We have a lot of negative attitudes toward heavy-weight people. Judging patients as too big or too fat produces physical and mental health effects,” said Joan C. Chrisler, PhD, the Class of ’43 Professor of Psychology at Connecticut College, New London. “Shame and disrespectful treatment can lead to delay in seeking health care, reluctance to return visits, or lower trust in the providers and their recommendations.”

A study of more than 300 autopsy reports showed that obese patients were 1.65 times more likely than normal weight and underweight groups combined were to have medical conditions such as endocarditis, ischemic bowel disease, and lung cancer that were not diagnosed, Dr. Chrisler said in a press release (Am J Clin Pathol. 2006 Jan;125[1]:127-31).

In addition to preventing patients from seeking care, Dr. Chrisler said in the release, unfamiliarity with the dosing adjustments sometimes required on medications based on the body mass index of patients affects the quality of care. She cited a retrospective study showing that emergency physicians frequently underdose common antibiotics in the emergency department (Am J Emerg Med. 2012 Sep;30[7]:1212-4).

Dr. Maureen C. McHugh
Maureen C. McHugh, PhD, stressed the importance of understanding the origins of fat shaming and its destructive effects.

“People aren’t born repulsed by fat people,” said Dr. McHugh, professor of psychology at Indiana University of Pennsylvania. “Fat hate is learned within the family.”

They encouraged more sensitivity from medical professionals when it comes to treating overweight and obese patients, such as providing changing gowns of different sizes in examination rooms and weighing patients in private areas of the medical office.

Dr. Chrisler and Dr. McHugh said weight stigma should be addressed in medicine and psychology through training and research, and in working with patients who are obese. “Treatments should focus on mental and physical health as the desired outcomes for therapy rather than weight,” Dr. McHugh said.

Dr. Chrisler, coauthor of a recent article on sizeism (Fat Studies. 2017 Aug;6[1]:38-53), had no disclosures. Dr. McHugh also had no disclosures.

 

Obesity is a major modifiable cause of diseases of the digestive tract that routinely goes unaddressed. The AGA Obesity Practice Guide was created to support gastroenterologists leading a care team to help patients with obesity achieve a healthy weight. The AGA Obesity Practice Guide provides a comprehensive, multi-disciplinary process to personalize innovative obesity care for safe and effective weight management. Learn more at www.gastro.org/obesity.

Publications
Publications
Topics
Article Type
Sections
Article Source

EXPERT ANALYSIS FROM THE 2017 APA CONVENTION

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

Radiographic progression in axial spondyloarthritis moves slowly in first 5 years

Article Type
Changed
Sat, 12/08/2018 - 14:18

 

Sacroiliac joint radiographic progression during the first 5 years of the onset of axial spondyloarthritis occurs to an extent related to the degree of inflammation seen on MRI at baseline, according to new findings from 416 French patients in the DESIR cohort.

Maxime Dougados, MD, of Paris Descartes University, and his colleagues found that 15% of patients at baseline met modified New York (mNY) criteria – and therefore had radiographic axial spondyloarthritis (r-axSpA) – and this increased to 20% at 5 years. During the 5-year follow-up, the net percentage of patients who progressed was 5% (those who went from nonradiographic axial spondyloarthritis [nr-axSpA] to r-axSpA minus those who regressed from r-axSpA to nr-axSpA). Overall, 13% changed at least one grade on mNY criteria, and if an mNY criteria grade change from zero to one was not considered, only 10% experienced a change in at least one grade. These patients overall had a mean age of 34 years and had inflammatory back pain that had lasted at least 3 months but less than 3 years.

Dr. Maxime Dougados
After 5 years, HLA-B27–positive patients with sacroiliac joint (SIJ) inflammation on MRI at baseline had more than fivefold greater odds of developing radiographic damage than did those without SIJ inflammation on MRI (odds ratio, 5.39; 95% confidence interval, 3.25-8.94), and although the association was diminished in HLA-B27–negative patients, it was still statistically significant (OR, 2.16; 95% CI 1.04-4.51).

“The association between baseline MRI inflammation and 5-year SIJ damage was consistently found, regardless of the analytical method and the definition of SIJ progression,” the investigators wrote.

The estimated risk for progression by at least one mNY criteria grade varied from as high as 18% in HLA-B27–positive individuals with baseline SIJ inflammation on MRI and elevated C-reactive protein to just 1% in those who were negative for those three variables.

Read the full report online (Ann Rheum Dis. 2017 Jul 6. doi: 10.1136/annrheumdis-2017-211596).

Publications
Topics
Sections

 

Sacroiliac joint radiographic progression during the first 5 years of the onset of axial spondyloarthritis occurs to an extent related to the degree of inflammation seen on MRI at baseline, according to new findings from 416 French patients in the DESIR cohort.

Maxime Dougados, MD, of Paris Descartes University, and his colleagues found that 15% of patients at baseline met modified New York (mNY) criteria – and therefore had radiographic axial spondyloarthritis (r-axSpA) – and this increased to 20% at 5 years. During the 5-year follow-up, the net percentage of patients who progressed was 5% (those who went from nonradiographic axial spondyloarthritis [nr-axSpA] to r-axSpA minus those who regressed from r-axSpA to nr-axSpA). Overall, 13% changed at least one grade on mNY criteria, and if an mNY criteria grade change from zero to one was not considered, only 10% experienced a change in at least one grade. These patients overall had a mean age of 34 years and had inflammatory back pain that had lasted at least 3 months but less than 3 years.

Dr. Maxime Dougados
After 5 years, HLA-B27–positive patients with sacroiliac joint (SIJ) inflammation on MRI at baseline had more than fivefold greater odds of developing radiographic damage than did those without SIJ inflammation on MRI (odds ratio, 5.39; 95% confidence interval, 3.25-8.94), and although the association was diminished in HLA-B27–negative patients, it was still statistically significant (OR, 2.16; 95% CI 1.04-4.51).

“The association between baseline MRI inflammation and 5-year SIJ damage was consistently found, regardless of the analytical method and the definition of SIJ progression,” the investigators wrote.

The estimated risk for progression by at least one mNY criteria grade varied from as high as 18% in HLA-B27–positive individuals with baseline SIJ inflammation on MRI and elevated C-reactive protein to just 1% in those who were negative for those three variables.

Read the full report online (Ann Rheum Dis. 2017 Jul 6. doi: 10.1136/annrheumdis-2017-211596).

 

Sacroiliac joint radiographic progression during the first 5 years of the onset of axial spondyloarthritis occurs to an extent related to the degree of inflammation seen on MRI at baseline, according to new findings from 416 French patients in the DESIR cohort.

Maxime Dougados, MD, of Paris Descartes University, and his colleagues found that 15% of patients at baseline met modified New York (mNY) criteria – and therefore had radiographic axial spondyloarthritis (r-axSpA) – and this increased to 20% at 5 years. During the 5-year follow-up, the net percentage of patients who progressed was 5% (those who went from nonradiographic axial spondyloarthritis [nr-axSpA] to r-axSpA minus those who regressed from r-axSpA to nr-axSpA). Overall, 13% changed at least one grade on mNY criteria, and if an mNY criteria grade change from zero to one was not considered, only 10% experienced a change in at least one grade. These patients overall had a mean age of 34 years and had inflammatory back pain that had lasted at least 3 months but less than 3 years.

Dr. Maxime Dougados
After 5 years, HLA-B27–positive patients with sacroiliac joint (SIJ) inflammation on MRI at baseline had more than fivefold greater odds of developing radiographic damage than did those without SIJ inflammation on MRI (odds ratio, 5.39; 95% confidence interval, 3.25-8.94), and although the association was diminished in HLA-B27–negative patients, it was still statistically significant (OR, 2.16; 95% CI 1.04-4.51).

“The association between baseline MRI inflammation and 5-year SIJ damage was consistently found, regardless of the analytical method and the definition of SIJ progression,” the investigators wrote.

The estimated risk for progression by at least one mNY criteria grade varied from as high as 18% in HLA-B27–positive individuals with baseline SIJ inflammation on MRI and elevated C-reactive protein to just 1% in those who were negative for those three variables.

Read the full report online (Ann Rheum Dis. 2017 Jul 6. doi: 10.1136/annrheumdis-2017-211596).

Publications
Publications
Topics
Article Type
Click for Credit Status
Ready
Sections
Article Source

FROM ANNALS OF THE RHEUMATIC DISEASES

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

New genetic causes of ichthyoses likely to emerge

Article Type
Changed
Fri, 01/18/2019 - 16:57

 

CHICAGO– The way Keith Choate, MD, PhD, sees it, he and other clinicians are only beginning to scratch the surface on their understanding of the genetic causes of ichthyosis and ichthyosis syndromes.

“Despite the fact that we now understand that there are about 21,000 genes in the genome, we have very superficial understanding and functions known for only about 4,000 genes,” Dr. Choate of the departments of dermatology and genetics at Yale University, New Haven, Conn., said at the World Congress of Pediatric Dermatology. “Clinical insight is what’s driving all of the discovery. We continue to find new disorders, and these next-generation technologies really permit us to find the genetic basis for those disorders. I like to say that it’s the disorders that we don’t read about in the textbook that end up being the ones that are most interesting.”

Ichthyoses are cardinal disorders that occur when the normal pattern of epidermal differentiation is disrupted and leads to compensatory hyperproliferation. Clinically, ichthyoses present in a variety of ways, and more than 50 genes can cause them.

Dr. Keith Choate
“These genes encode proteins of diverse function, from enzymatic proteins to membrane transporters to structural proteins,” Dr. Choate said. “I think the question we have is, is there anything left to discover? What is the potential for gene discovery? We and others have found that there are new causes of ichthyosis, and in clinical practice, we’ve come to understand that there are many disorders for which we really don’t have any known genetic causes. This includes many palmoplantar keratodermas and erythrokeratodermas, syndromic cases, and subtypes of congenital ichthyosis, particularly milder types, and unusual or unique cases.”

Dr. Choate is the principal investigator of the National Registry for Ichthyosis and Related Skin Types, which has been recruiting kindreds of ichthyosis patients within the United States and internationally. To date, they have provided genetic diagnoses for 674 of the 880 cases enrolled. The process involves phenotyping with a clinical history and photography, obtaining DNA from blood or saliva, and prescreening the DNA samples for mutations in 51 genes currently implicated in ichthyosis. Subjects without known mutations undergo whole exome or genome sequencing.

“We have created a unique resource in doing this,” he said. “Genotyped/phenotyped patients provide a resource for clinical and translational studies in disorders of keratinization.”

When the researchers examined patients from the registry who have epidermolytic presentations, 100% had mutations in the known genes, “so the biopsy is diagnostic,” Dr. Choate said. “About 80% have mutations in keratin 10, about 13% have mutations in keratin 1, and another 6% have mutations in keratin 2.”

About 85% of patients with recessive and syndromic disorders have mutations in this same 51-gene panel; 15% of cases don’t have mutations in those genes. “This is a similar fraction to what my colleagues have found at a variety of institutions around the world,” Dr. Choate said. “What’s fascinating is that this 15% has been the source of remarkable discovery.”

He then discussed three cases of a novel erythrokeratoderma phenotype that were referred to the registry. In one case, a boy had pervasive intellectual disability, congenital alopecia, and absence of the eyebrows. “Within the first days of life, he developed a significant erythroderma with copious scaling of the skin that persisted throughout life and that was unresponsive to a variety of different therapeutic interventions, including immunosuppressant medications,” Dr. Choate said. “He had nail dystrophy and progressive enamel decay with severe caries, leading to loss of all of his teeth by the age of 6.”

Another case was a child who died of cardiomyopathy at about 3 years of age. He had congenital absence of the eyebrows and eyelashes, nail dystrophy, and scaling. “About 2 weeks before his death, he had a skin biopsy that we would ultimately repurpose to identify a new genetic cause of what we would call the erythrokeratodermia-cardiomyopathy syndrome,” Dr. Choate said. “It included features of congenital erythroderma, defective dental enamel, abnormal nails, and progressive and lethal cardiomyopathy. When we did exome sequencing, we found that all three of these patients showed tightly clustered de novo mutations in a gene called desmoplakin (DSP). Other DSP mutations do not cause erythrokeratoderma.”

Electron microscopy showed aggregates of desmosomes, normal corneodesmosomes, widening of intercellular spaces, and abnormal lipid secretion. The finding led the researchers to conclude that clustered DSP mutations cause a novel cutaneous phenotype with erythrokeratoderma and progressive cardiomyopathy. “The next time an insurer refuses to do genetic testing for you in a patient who has erythrokeratoderma, this is the disorder that you want to cite as the reason why you need to do genetic testing,” he said.

In a recent study, Dr. Choate and his associates identified the genetic cause for a rare subtype of progressive symmetric erythrokeratoderma (PSEK), a disorder that features thick facial plaques and thickened palms and soles (Am J Hum Genet. 2017 Jun 1;100[6]:978-84). Histology reveals a thickened epidermis, loss of granular layer, and retention of nuclei in the stratum corneum. They discovered that PSEK was caused by mutations in 3-ketodihydrosphingosine reductase (KDSR), an enzyme that is central to de novo ceramides in skin.

“Ceramides are secreted by keratinocytes with cholesterol and free fatty acids to form the cutaneous lipid barrier,” he explained. “They also regulate cutaneous proliferation and differentiation. One of the things this story in particular told us was, when you find just one mutation and a compelling candidate gene and can’t find the other, it’s often because of how you’re approaching detection. In two of our cases, genome sequencing was necessary to find a large inversion, which disrupted the encoded protein. Finally, the challenge of studying ceramides is that it’s hard to get cells in culture to produce them. Therefore, we had to work with collaborators in yeast biology to prove pathogenesis.”

Dr. Choate cited other recent developments, including the discovery that familial pityriasis rubra pilaris is caused by mutations in CARD14, which is a known activator of nuclear factor kappa B signaling (Am J Hum Genet. 2012 Jul 13;91[1]:163-70). This led to the subsequent use of ustekinumab for patients with familial pityriasis rubra pilaris. Another group of researchers found that SULT2B1 encodes sulfotransferase family 2B member 1 and is central to epidermal cholesterol metabolism (Am J Hum Genet. 2017 Jun 1;100[6]:926-39).

“There are still new genetic causes of ichthyosis to be found, particularly cases that don’t meet the textbook criteria for the disorder,” he concluded. “Severe, dominant disorders primarily due to de novo mutations are fertile ground for discovery. Genetic investigation is critical to our understanding of disease biology and biology of the skin. It’s also potentially relevant to outcomes of therapy. [Erythrokeratodermia-cardiomyopathy syndrome] highlights the potential for comorbidities, and the efficacy of ustekinumab in familial [pityriasis rubra pilaris] highlights the therapeutic importance of understanding the pathway underlying the disease.”

Dr. Choate reported having no financial disclosures.
 

 

 

Meeting/Event
Publications
Topics
Sections
Meeting/Event
Meeting/Event
Related Articles

 

CHICAGO– The way Keith Choate, MD, PhD, sees it, he and other clinicians are only beginning to scratch the surface on their understanding of the genetic causes of ichthyosis and ichthyosis syndromes.

“Despite the fact that we now understand that there are about 21,000 genes in the genome, we have very superficial understanding and functions known for only about 4,000 genes,” Dr. Choate of the departments of dermatology and genetics at Yale University, New Haven, Conn., said at the World Congress of Pediatric Dermatology. “Clinical insight is what’s driving all of the discovery. We continue to find new disorders, and these next-generation technologies really permit us to find the genetic basis for those disorders. I like to say that it’s the disorders that we don’t read about in the textbook that end up being the ones that are most interesting.”

Ichthyoses are cardinal disorders that occur when the normal pattern of epidermal differentiation is disrupted and leads to compensatory hyperproliferation. Clinically, ichthyoses present in a variety of ways, and more than 50 genes can cause them.

Dr. Keith Choate
“These genes encode proteins of diverse function, from enzymatic proteins to membrane transporters to structural proteins,” Dr. Choate said. “I think the question we have is, is there anything left to discover? What is the potential for gene discovery? We and others have found that there are new causes of ichthyosis, and in clinical practice, we’ve come to understand that there are many disorders for which we really don’t have any known genetic causes. This includes many palmoplantar keratodermas and erythrokeratodermas, syndromic cases, and subtypes of congenital ichthyosis, particularly milder types, and unusual or unique cases.”

Dr. Choate is the principal investigator of the National Registry for Ichthyosis and Related Skin Types, which has been recruiting kindreds of ichthyosis patients within the United States and internationally. To date, they have provided genetic diagnoses for 674 of the 880 cases enrolled. The process involves phenotyping with a clinical history and photography, obtaining DNA from blood or saliva, and prescreening the DNA samples for mutations in 51 genes currently implicated in ichthyosis. Subjects without known mutations undergo whole exome or genome sequencing.

“We have created a unique resource in doing this,” he said. “Genotyped/phenotyped patients provide a resource for clinical and translational studies in disorders of keratinization.”

When the researchers examined patients from the registry who have epidermolytic presentations, 100% had mutations in the known genes, “so the biopsy is diagnostic,” Dr. Choate said. “About 80% have mutations in keratin 10, about 13% have mutations in keratin 1, and another 6% have mutations in keratin 2.”

About 85% of patients with recessive and syndromic disorders have mutations in this same 51-gene panel; 15% of cases don’t have mutations in those genes. “This is a similar fraction to what my colleagues have found at a variety of institutions around the world,” Dr. Choate said. “What’s fascinating is that this 15% has been the source of remarkable discovery.”

He then discussed three cases of a novel erythrokeratoderma phenotype that were referred to the registry. In one case, a boy had pervasive intellectual disability, congenital alopecia, and absence of the eyebrows. “Within the first days of life, he developed a significant erythroderma with copious scaling of the skin that persisted throughout life and that was unresponsive to a variety of different therapeutic interventions, including immunosuppressant medications,” Dr. Choate said. “He had nail dystrophy and progressive enamel decay with severe caries, leading to loss of all of his teeth by the age of 6.”

Another case was a child who died of cardiomyopathy at about 3 years of age. He had congenital absence of the eyebrows and eyelashes, nail dystrophy, and scaling. “About 2 weeks before his death, he had a skin biopsy that we would ultimately repurpose to identify a new genetic cause of what we would call the erythrokeratodermia-cardiomyopathy syndrome,” Dr. Choate said. “It included features of congenital erythroderma, defective dental enamel, abnormal nails, and progressive and lethal cardiomyopathy. When we did exome sequencing, we found that all three of these patients showed tightly clustered de novo mutations in a gene called desmoplakin (DSP). Other DSP mutations do not cause erythrokeratoderma.”

Electron microscopy showed aggregates of desmosomes, normal corneodesmosomes, widening of intercellular spaces, and abnormal lipid secretion. The finding led the researchers to conclude that clustered DSP mutations cause a novel cutaneous phenotype with erythrokeratoderma and progressive cardiomyopathy. “The next time an insurer refuses to do genetic testing for you in a patient who has erythrokeratoderma, this is the disorder that you want to cite as the reason why you need to do genetic testing,” he said.

In a recent study, Dr. Choate and his associates identified the genetic cause for a rare subtype of progressive symmetric erythrokeratoderma (PSEK), a disorder that features thick facial plaques and thickened palms and soles (Am J Hum Genet. 2017 Jun 1;100[6]:978-84). Histology reveals a thickened epidermis, loss of granular layer, and retention of nuclei in the stratum corneum. They discovered that PSEK was caused by mutations in 3-ketodihydrosphingosine reductase (KDSR), an enzyme that is central to de novo ceramides in skin.

“Ceramides are secreted by keratinocytes with cholesterol and free fatty acids to form the cutaneous lipid barrier,” he explained. “They also regulate cutaneous proliferation and differentiation. One of the things this story in particular told us was, when you find just one mutation and a compelling candidate gene and can’t find the other, it’s often because of how you’re approaching detection. In two of our cases, genome sequencing was necessary to find a large inversion, which disrupted the encoded protein. Finally, the challenge of studying ceramides is that it’s hard to get cells in culture to produce them. Therefore, we had to work with collaborators in yeast biology to prove pathogenesis.”

Dr. Choate cited other recent developments, including the discovery that familial pityriasis rubra pilaris is caused by mutations in CARD14, which is a known activator of nuclear factor kappa B signaling (Am J Hum Genet. 2012 Jul 13;91[1]:163-70). This led to the subsequent use of ustekinumab for patients with familial pityriasis rubra pilaris. Another group of researchers found that SULT2B1 encodes sulfotransferase family 2B member 1 and is central to epidermal cholesterol metabolism (Am J Hum Genet. 2017 Jun 1;100[6]:926-39).

“There are still new genetic causes of ichthyosis to be found, particularly cases that don’t meet the textbook criteria for the disorder,” he concluded. “Severe, dominant disorders primarily due to de novo mutations are fertile ground for discovery. Genetic investigation is critical to our understanding of disease biology and biology of the skin. It’s also potentially relevant to outcomes of therapy. [Erythrokeratodermia-cardiomyopathy syndrome] highlights the potential for comorbidities, and the efficacy of ustekinumab in familial [pityriasis rubra pilaris] highlights the therapeutic importance of understanding the pathway underlying the disease.”

Dr. Choate reported having no financial disclosures.
 

 

 

 

CHICAGO– The way Keith Choate, MD, PhD, sees it, he and other clinicians are only beginning to scratch the surface on their understanding of the genetic causes of ichthyosis and ichthyosis syndromes.

“Despite the fact that we now understand that there are about 21,000 genes in the genome, we have very superficial understanding and functions known for only about 4,000 genes,” Dr. Choate of the departments of dermatology and genetics at Yale University, New Haven, Conn., said at the World Congress of Pediatric Dermatology. “Clinical insight is what’s driving all of the discovery. We continue to find new disorders, and these next-generation technologies really permit us to find the genetic basis for those disorders. I like to say that it’s the disorders that we don’t read about in the textbook that end up being the ones that are most interesting.”

Ichthyoses are cardinal disorders that occur when the normal pattern of epidermal differentiation is disrupted and leads to compensatory hyperproliferation. Clinically, ichthyoses present in a variety of ways, and more than 50 genes can cause them.

Dr. Keith Choate
“These genes encode proteins of diverse function, from enzymatic proteins to membrane transporters to structural proteins,” Dr. Choate said. “I think the question we have is, is there anything left to discover? What is the potential for gene discovery? We and others have found that there are new causes of ichthyosis, and in clinical practice, we’ve come to understand that there are many disorders for which we really don’t have any known genetic causes. This includes many palmoplantar keratodermas and erythrokeratodermas, syndromic cases, and subtypes of congenital ichthyosis, particularly milder types, and unusual or unique cases.”

Dr. Choate is the principal investigator of the National Registry for Ichthyosis and Related Skin Types, which has been recruiting kindreds of ichthyosis patients within the United States and internationally. To date, they have provided genetic diagnoses for 674 of the 880 cases enrolled. The process involves phenotyping with a clinical history and photography, obtaining DNA from blood or saliva, and prescreening the DNA samples for mutations in 51 genes currently implicated in ichthyosis. Subjects without known mutations undergo whole exome or genome sequencing.

“We have created a unique resource in doing this,” he said. “Genotyped/phenotyped patients provide a resource for clinical and translational studies in disorders of keratinization.”

When the researchers examined patients from the registry who have epidermolytic presentations, 100% had mutations in the known genes, “so the biopsy is diagnostic,” Dr. Choate said. “About 80% have mutations in keratin 10, about 13% have mutations in keratin 1, and another 6% have mutations in keratin 2.”

About 85% of patients with recessive and syndromic disorders have mutations in this same 51-gene panel; 15% of cases don’t have mutations in those genes. “This is a similar fraction to what my colleagues have found at a variety of institutions around the world,” Dr. Choate said. “What’s fascinating is that this 15% has been the source of remarkable discovery.”

He then discussed three cases of a novel erythrokeratoderma phenotype that were referred to the registry. In one case, a boy had pervasive intellectual disability, congenital alopecia, and absence of the eyebrows. “Within the first days of life, he developed a significant erythroderma with copious scaling of the skin that persisted throughout life and that was unresponsive to a variety of different therapeutic interventions, including immunosuppressant medications,” Dr. Choate said. “He had nail dystrophy and progressive enamel decay with severe caries, leading to loss of all of his teeth by the age of 6.”

Another case was a child who died of cardiomyopathy at about 3 years of age. He had congenital absence of the eyebrows and eyelashes, nail dystrophy, and scaling. “About 2 weeks before his death, he had a skin biopsy that we would ultimately repurpose to identify a new genetic cause of what we would call the erythrokeratodermia-cardiomyopathy syndrome,” Dr. Choate said. “It included features of congenital erythroderma, defective dental enamel, abnormal nails, and progressive and lethal cardiomyopathy. When we did exome sequencing, we found that all three of these patients showed tightly clustered de novo mutations in a gene called desmoplakin (DSP). Other DSP mutations do not cause erythrokeratoderma.”

Electron microscopy showed aggregates of desmosomes, normal corneodesmosomes, widening of intercellular spaces, and abnormal lipid secretion. The finding led the researchers to conclude that clustered DSP mutations cause a novel cutaneous phenotype with erythrokeratoderma and progressive cardiomyopathy. “The next time an insurer refuses to do genetic testing for you in a patient who has erythrokeratoderma, this is the disorder that you want to cite as the reason why you need to do genetic testing,” he said.

In a recent study, Dr. Choate and his associates identified the genetic cause for a rare subtype of progressive symmetric erythrokeratoderma (PSEK), a disorder that features thick facial plaques and thickened palms and soles (Am J Hum Genet. 2017 Jun 1;100[6]:978-84). Histology reveals a thickened epidermis, loss of granular layer, and retention of nuclei in the stratum corneum. They discovered that PSEK was caused by mutations in 3-ketodihydrosphingosine reductase (KDSR), an enzyme that is central to de novo ceramides in skin.

“Ceramides are secreted by keratinocytes with cholesterol and free fatty acids to form the cutaneous lipid barrier,” he explained. “They also regulate cutaneous proliferation and differentiation. One of the things this story in particular told us was, when you find just one mutation and a compelling candidate gene and can’t find the other, it’s often because of how you’re approaching detection. In two of our cases, genome sequencing was necessary to find a large inversion, which disrupted the encoded protein. Finally, the challenge of studying ceramides is that it’s hard to get cells in culture to produce them. Therefore, we had to work with collaborators in yeast biology to prove pathogenesis.”

Dr. Choate cited other recent developments, including the discovery that familial pityriasis rubra pilaris is caused by mutations in CARD14, which is a known activator of nuclear factor kappa B signaling (Am J Hum Genet. 2012 Jul 13;91[1]:163-70). This led to the subsequent use of ustekinumab for patients with familial pityriasis rubra pilaris. Another group of researchers found that SULT2B1 encodes sulfotransferase family 2B member 1 and is central to epidermal cholesterol metabolism (Am J Hum Genet. 2017 Jun 1;100[6]:926-39).

“There are still new genetic causes of ichthyosis to be found, particularly cases that don’t meet the textbook criteria for the disorder,” he concluded. “Severe, dominant disorders primarily due to de novo mutations are fertile ground for discovery. Genetic investigation is critical to our understanding of disease biology and biology of the skin. It’s also potentially relevant to outcomes of therapy. [Erythrokeratodermia-cardiomyopathy syndrome] highlights the potential for comorbidities, and the efficacy of ustekinumab in familial [pityriasis rubra pilaris] highlights the therapeutic importance of understanding the pathway underlying the disease.”

Dr. Choate reported having no financial disclosures.
 

 

 

Publications
Publications
Topics
Article Type
Click for Credit Status
Ready
Sections
Article Source

AT WCPD 2017

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default